Avedro CEO Reza Zadno Walks Us Through the Recent IPO, Reimbursement Wins, and Future Potential

OIS Podcast | Ophthalmology's leading Podcast

English - April 24, 2019 22:00 - 31 minutes - 14.6 MB - ★★★★★ - 30 ratings
Investing Business Health & Fitness ophthalmology investment venture capital entrepreneurs oftalmólogo ophthalmic key opinion leader seco ascrs aao Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Oculis CEO Riad Sherif Talks About Novartis, Alcon, and What’s Promising in His Company’s Pipeline

Next Episode: Novartis’ Patrick Mooney Gives Inside Look on the Impact of Alcon Spin-Out, Bid to Acquire Xiidra

Avedro Inc. went public on Feb. 14, raising $70 million with its shares pricing at, coincidentally, $14. We talk with Reza Zadno, CEO and president, about the IPO process, which, as you might imagine, she says is as difficult as it looks. We’ll also talk business. Avedro, of course, is a commercial enterprise now, reporting growing sales on its Corneal Crosslinking System that can be used to treat keratoconus, a non-inflammatory eye condition that weakens and misshapes the cornea. What does the future hold for the start-up?